Prevention of autoimmune diabetes by FTY720 in nonobese diabetic mice - PubMed (original) (raw)
Prevention of autoimmune diabetes by FTY720 in nonobese diabetic mice
Takashi Maki et al. Transplantation. 2002.
Abstract
Background: FTY720 prevents allograft rejection with remarkable potency without inducing generalized immunosuppression. We determined the effect of FTY720 on development of autoimmune diabetes in nonobese diabetic (NOD) mice.
Methods: NOD mice were given FTY720 (0.5 mg/kg, orally) five times per week starting from 4 weeks of age.
Results: Daily FTY720 prevented development of diabetes in 15 of 16 treated mice, whereas 70% of untreated NOD mice became diabetic by 35 weeks of age. Withdrawal of FTY720 at 35 weeks of age led to development of diabetes within 2 weeks in five mice, whereas the remaining mice maintained diabetes-free conditions for up to 44 weeks of age. No side effect of the drug was seen throughout the treatment period. FTY720 also prevented cyclophosphamide-induced diabetes in NOD mice.
Conclusions: FTY720 is a safe and benign therapeutic agent that may be used chronically in prediabetic individuals.
Similar articles
- Prevention and cure of autoimmune diabetes in nonobese diabetic mice by continuous administration of FTY720.
Maki T, Gottschalk R, Ogawa N, Monaco AP. Maki T, et al. Transplantation. 2005 May 15;79(9):1051-5. doi: 10.1097/01.tp.0000161220.87548.ee. Transplantation. 2005. PMID: 15880042 - Long-term islet graft survival in streptozotocin- and autoimmune-induced diabetes models by immunosuppressive and potential insulinotropic agent FTY720.
Fu F, Hu S, Deleo J, Li S, Hopf C, Hoover J, Wang S, Brinkmann V, Lake P, Shi VC. Fu F, et al. Transplantation. 2002 May 15;73(9):1425-30. doi: 10.1097/00007890-200205150-00011. Transplantation. 2002. PMID: 12023620 - The immune modulator FYT720 prevents autoimmune diabetes in nonobese diabetic mice.
Yang Z, Chen M, Fialkow LB, Ellett JD, Wu R, Brinkmann V, Nadler JL, Lynch KR. Yang Z, et al. Clin Immunol. 2003 Apr;107(1):30-5. doi: 10.1016/s1521-6616(02)00054-2. Clin Immunol. 2003. PMID: 12738247 - FTY720: altered lymphocyte traffic results in allograft protection.
Brinkmann V, Pinschewer DD, Feng L, Chen S. Brinkmann V, et al. Transplantation. 2001 Sep 15;72(5):764-9. doi: 10.1097/00007890-200109150-00002. Transplantation. 2001. PMID: 11571432 Review. No abstract available. - FTY720: a new immunosuppressive agent with novel mechanism(s) of action.
Kahan BD. Kahan BD. Transplant Proc. 1998 Aug;30(5):2210-3. doi: 10.1016/s0041-1345(98)00593-4. Transplant Proc. 1998. PMID: 9723444 Review. No abstract available.
Cited by
- From markers to molecular mechanisms: type 1 diabetes in the post-GWAS era.
Baxter AG, Jordan MA. Baxter AG, et al. Rev Diabet Stud. 2012 Winter;9(4):201-23. doi: 10.1900/RDS.2012.9.201. Epub 2012 Dec 28. Rev Diabet Stud. 2012. PMID: 23804261 Free PMC article. Review. - FTY720 Regulates Mitochondria Biogenesis in Dendritic Cells to Prevent Kidney Ischemic Reperfusion Injury.
Rousselle TV, Kuscu C, Kuscu C, Schlegel K, Huang L, Namwanje M, Eason JD, Makowski L, Maluf D, Mas V, Bajwa A. Rousselle TV, et al. Front Immunol. 2020 Jun 23;11:1278. doi: 10.3389/fimmu.2020.01278. eCollection 2020. Front Immunol. 2020. PMID: 32670281 Free PMC article. - Chronic sphingosine 1-phosphate 1 receptor activation attenuates early-stage diabetic nephropathy independent of lymphocytes.
Awad AS, Rouse MD, Khutsishvili K, Huang L, Bolton WK, Lynch KR, Okusa MD. Awad AS, et al. Kidney Int. 2011 May;79(10):1090-8. doi: 10.1038/ki.2010.544. Epub 2011 Feb 2. Kidney Int. 2011. PMID: 21289599 Free PMC article. - Therapeutic approach for type 1 diabetes mellitus using the novel immunomodulator FTY720 (fingolimod) in combination with once-daily injection of insulin glargine in non-obese diabetic mice.
Tsuji T, Inoue M, Yoshida Y, Fujita T, Kaino Y, Kohno T. Tsuji T, et al. J Diabetes Investig. 2012 Mar 28;3(2):132-7. doi: 10.1111/j.2040-1124.2011.00160.x. J Diabetes Investig. 2012. PMID: 24843556 Free PMC article. - Functional Lipids in Autoimmune Inflammatory Diseases.
Cas MD, Roda G, Li F, Secundo F. Cas MD, et al. Int J Mol Sci. 2020 Apr 27;21(9):3074. doi: 10.3390/ijms21093074. Int J Mol Sci. 2020. PMID: 32349258 Free PMC article. Review.
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical